secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0001157523-23-000670
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Q1 revenue $900M (+8% reported, +10% organic); EPS $2.55; raises 2023 guidance
--------------------------------------------------------------------------------

- Q1 revenue $900M, up 8% reported, 10% organic; CAG Diagnostics recurring revenue up 9% reported, 12% organic.
- EPS $2.55, up 12% reported, 18% comparable; includes $0.06 tax benefit and $0.11 negative FX impact.
- Raises FY2023 revenue guidance to $3,615M-$3,700M (7.5%-10%) and EPS guidance to $9.33-$9.75 (16%-22% reported).
- Record Q1 global premium instrument placements; U.S. CAG Diagnostics organic recurring revenue grew 14%, 1,350 bps premium to clinic visits.
- Operating margin 31.1%, up 150 bps reported, 210 bps comparable; gross margin 60.3%, up 70 bps reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000115752323000670/0001157523-23-000670-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000115752323000670/a53391037.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-000670

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer